Accustem Sciences Inc. Overview
Industry: Biotechnology
Sector: Healthcare
Accustem Sciences Inc., a clinical stage diagnostics company, develops and commercializes products for the treatment and management of various cancers. Its primary product candidate is StemPrintER, a 20-gene prognostic assay to predict the risk of distant recurrence in luminal breast cancer patients. The company was incorporated in 2021 and is headquartered in New York, New York.
Accustem Sciences Inc. is evaluated using Mavefund's quality framework: growing earnings, durable profit margins, conservative leverage, strong return on equity, and disciplined share repurchases.
Score
Price History & Performance
Review Accustem Sciences Inc. in context before unlocking the interactive price chart, financial overlays, and downloadable ratio tables.
Recent News
Accustem Sciences Inc. Competitors
Accustem Sciences Inc. operates in the Biotechnology industry within the Healthcare sector. Unlock the full page to compare peer rankings, valuation quality, profitability, leverage, and growth trends.
Earnings Per Share
EPS quality is one of the core Mavefund signals. Sign up to continue into the detailed EPS, ROE, margin, share buyback, leverage, and financial ratio analysis.
Continue the analysis
Sign up to unlock ROE, net margin, share buyback, leverage, financial ratios, peer charts, and downloads.
View plans